May maybes as Spanish in prepares to pay back d€bt €Billions to pharma
This article was originally published in Scrip
Executive Summary
There is soon to be some relief for pharmaceutical companies in Spain that have been struggling to recover hospital debts related to drug purchases totalling €6.3 billion. A €35 billion "liquidity injection" from the central Spanish government should see regional and local authorities start to pay back providers, said the treasury this week. However, it is far from clear that the financial jab in the arm provides any comfort for the pharma industry beyond the immediate future.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.